ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A ... end-stage renal disease, or death. Secondary outcomes included changes ...

Patients with IgA nephropathy and severe proteinuria have a high lifetime risk of kidney failure. The efficacy and safety of the selective endothelin type A receptor antagonist atrasentan in ...

recently described the potential of the endothelin-A antagonist avosentan ... A trial of the two higher doses of avosentan with hard renal outcomes was then initiated, but was terminated early ...

A novel drug significantly reduced IgA nephropathy-related proteinuria, according to interim findings of the ALIGN study. In ...